2019 logo_150x35_jpg.jpg
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
June 13, 2022 16:05 ET | Novan, Inc.
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering...
2019 logo_150x35_jpg.jpg
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
June 09, 2022 08:30 ET | Novan, Inc.
DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to...
2019 logo_150x35_jpg.jpg
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
May 19, 2022 09:05 ET | Novan, Inc.
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of...
2019 logo_150x35_jpg.jpg
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 06:30 ET | Novan, Inc.
– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1 2021 – – Ongoing activities toward...
2019 logo_150x35_jpg.jpg
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
May 06, 2022 09:00 ET | Novan, Inc.
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May...
2019 logo_150x35_jpg.jpg
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event
April 20, 2022 09:05 ET | Novan, Inc.
DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology...
2019 logo_150x35_jpg.jpg
Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting
March 24, 2022 09:00 ET | Novan, Inc.
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for...
2019 logo_150x35_jpg.jpg
Novan, Inc. to Present at Two Upcoming Investor Conferences
March 14, 2022 09:00 ET | Novan, Inc.
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
2019 logo_150x35_jpg.jpg
Novan Acquires EPI Health, a Specialty Dermatology Company
March 11, 2022 06:35 ET | Novan, Inc.
– EPI Health promotes four prescription products posting 2021 operating revenue of $17.6 million – – Acquisition forward integrates Novan with complementary commercial infrastructure to drive...
2019 logo_150x35_jpg.jpg
Novan Reports Full Year 2021 Financial Results and Provides Corporate Update
February 22, 2022 07:00 ET | Novan, Inc.
– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline...